Adela Cañete

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial

Ruth Ladenstein, Ulrike Pötschger, Andrew D.J. Pearson et al. · The Lancet Oncology · 2017 · 334 citations · Full text

Oncology, Medicine, Versus Carboplatin +8

High Oct4 expression: implications in the pathogenesis of neuroblastic tumours

Ezequiel Monferrer, Rebeca Burgos‐Panadero, Maite Blanquer-Maceiras et al. · BMC Cancer · 2019 · 201 citations · Full text

Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age.

Nai‐Kong V. Cheung, Brian H. Kushner, Irene Y. Cheung et al. · Journal of Clinical Oncology · 1998 · 197 citations

Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study

Joëlle Vermeulen, Katleen De Preter, Arlene Naranjo et al. · The Lancet Oncology · 2009 · 194 citations · Full text

Neuro-oncology, Pediatric Brain Tumors, Pediatric Neurosurgery +8

Long-term survival and cure fraction estimates for childhood cancer in Europe (EUROCARE-6): results from a population-based study

Laura Botta, Gemma Gatta, Riccardo Capocaccia et al. · The Lancet Oncology · 2022 · 167 citations · Full text

Cure Fraction Estimates, Cancer Epidemiology, Childhood Cancer +9